Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance.

Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance. Abstract Text:

Nam Q Nguyen,Katrina Ching,Robert J Fraser,Marianne J Chapman,Richard H Holloway,

OBJECTIVE: To determine the incidence of Clostridium difficile (CD) diarrhoea in feed-intolerant, critically ill patients who received erythromycin-based prokinetic therapy. DESIGN AND SETTING: Prospective observational study in a mixed intensive care unit. METHODS: The development of diarrhoea (>[Symbol: see text]3 loose, liquid stool per day with an estimated total volume[Symbol: see text]>/=[Symbol: see text]250[Symbol: see text]ml/day) was assessed in 180 consecutive critically ill patients who received prokinetic therapy (erythromycin only, n[Symbol: see text]=[Symbol: see text]53; metoclopramide, n[Symbol: see text]=[Symbol: see text]37; combination erythromycin/metoclopramide, n[Symbol: see text]=[Symbol: see text]90) for feed intolerance. Stool microscopy, culture and CD toxin assay were performed in all patients who developed diarrhoea during and after prokinetic therapy. Diarrhoea was deemed to be related to CD infection if CD toxin was detected. RESULTS: Demographics, antibiotic use and admission diagnosis were similar amongst the three patients groups. Diarrhoea developed in 72 (40%) patients, 9.9[Symbol: see text]+/-[Symbol: see text]0.8[Symbol: see text]days after commencement of therapy, none of whom was positive for CD toxin or bacterial infection. Parasitic infections were found in four aboriginal men from an area endemic for these infections. Diarrhoea was most prevalent in patients who received combination therapy (49%) and was more common than in those who received erythromycin alone (30%) and metoclopramide alone (32%). Diarrhoea was short-lasting with a mean duration of 3.6[Symbol: see text]+/-[Symbol: see text]1.2[Symbol: see text]days. CONCLUSIONS: In critical illness, diarrhoea following the administration of erythromycin at prokinetic doses is not associated with CD but may be related to pro-motility effects of the agent. Prokinetic therapy should be stopped at the onset of diarrhoea and prophylactic use should be strictly avoided.

Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance. Publishing Authors By Initials

NQ Nguyen,K Ching,RJ Fraser,MJ Chapman,RH Holloway,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Intensive care medicine

VOLUME: 34

Page Numbers: 169-73

Journal Abbreviation:

ISSN: 0342-4642

DAY: 15

MONTH: 08

YEAR: 2007

Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7704851

Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance.

AFFILIATION: Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, North Terrace, 5000, Adelaide, Australia.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Intensive Care Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance Related Publications

• A global comparison of national biodiesel production potentials.
• Antimicrobial resistance surveillance among commensal Escherichia coli in rural and urban areas in Southern India.
• Bigfoot anatomy.
• Crack-heroin speedball injection and its implications for vein care: qualitative study.
• Defective triggering of secondary peristalsis in patients with non-erosive reflux disease.
• Differential c-fos expression in the brain of male Japanese quail following exposure to stimuli that predict or do not predict the arrival of a female.
• Effect of crystallization heat treatment on the microstructure and biaxial strength of fluorrichterite glass-ceramics.
• Effect of particulate matter air pollution on hospital admissions and medical visits for lung and heart disease in two southeast Idaho cities.
• Enhanced neural activation in brain regions mediating sexual responses following exposure to a conditioned stimulus that predicts copulation.
• Gastric feed intolerance is not increased in critically ill patients with type II diabetes mellitus.
• Hospice or home? Expectations of end-of-life care among white and Chinese older people in the UK.
• Intramedullary pinning in fractured mandible.
• Is a sister in charge of anaesthetics necessary in the operating theatre?
• Methods for studying the time course of cell division in clones from individual L5178Y leukemia cells.
• Models of PTSD and traumatic stress: the importance of research "from bedside to bench to bedside".
• Multiwavelength Output from a Nd:YAG /Cr:LiSAF Hybrid Laser.
• Oxygen consumption by the isolated rat liver--effects of hematocrit, temperature, perfusion rate and oxygen tension.
• Prokinetic therapy for feed intolerance in critical illness: one drug or two?
• Prospective audit of emergency department transit times associated with entonox analgesia for reduction of the acute, traumatic dislocated shoulder.
• Protein damage in drop-on-demand printers.
• Quality of life in epilepsy, multiple sclerosis, and beyond.
• Recovery of volatile compounds from butter oil.
• Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance.
• Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
• SUICIDAL STRYCHNINE POISONING.
• The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illness.
• The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
• The relationship between blood glucose control and intolerance to enteral feeding during critical illness.
• Towards an empirical model of performance enhancing supplement use: A pilot study among high performance UK athletes.
• White light emission from single layer poly (n-vinylcarbazole) polymeric light-emitting devices by mixing singlet and triplet excimer emissions.